Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 717 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Function Clear all
Completed Not applicable Interventional Accepts healthy volunteers

SWAP-MEAT: Study With Appetizing Plant Food - Meat Eating Alternatives Trial

NCT03718988
View directory record Official record
Conditions
Microbiome, Immune Function, Cardiovascular Diseases
Interventions
Meat products, Plant Alternative products
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 22, 2026, 3:59 AM EDT
Recruiting Phase 1 Interventional

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

NCT05857969
View directory record Official record
Conditions
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Hodgkin Lymphoma, Refractory Childhood Malignant Germ Cell Neoplasm, Recurrent Childhood Brain Tumor, Recurrent Childhood Brainstem Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Ependymoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Gliosarcoma, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Childhood Malignant Solid Neoplasm, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Malignant Neoplasm, Refractory Childhood Malignant Neoplasm
Interventions
Functional Precision Medicine
Device
Lead sponsor
Florida International University
Other
Eligibility
1 Day to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 22, 2026, 3:59 AM EDT
Terminated Not applicable Interventional Results available

Impact of Respiratory Training in Lymphoma Survivors

NCT05938127
View directory record Official record
Conditions
Hodgkin Lymphoma, Non Hodgkin Lymphoma
Interventions
Inspiratory muscle strength training, Sham Inspiratory muscle strength training
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 22, 2026, 3:59 AM EDT
Completed Not applicable Interventional

From Clinic to Community: An Information and Communication Technology (ICT) Home-Based Exercise Training System for Translating Clinical Findings

NCT03108950
View directory record Official record
Conditions
Multiple Sclerosis, Stroke
Interventions
Movement to Music
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 22, 2026, 3:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immune and Endocrine Function in Post-Traumatic Stress Disorder

NCT00100490
View directory record Official record
Conditions
Post-Traumatic Stress Disorders
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2002
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 22, 2026, 3:59 AM EDT
Terminated No phase listed Observational

Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

NCT03777410
View directory record Official record
Conditions
Multiple Myeloma in Relapse
Interventions
Not listed
Lead sponsor
Travera Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Duarte, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 22, 2026, 3:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular Function

NCT03062878
View directory record Official record
Conditions
Breast Cancer, Lymphoma, Chemotherapy Effect
Interventions
Arterial blood pressure, Vascular Ultrasound, Venous blood sample, Skin microcirculatory blood flow
Other
Lead sponsor
Carl Ade, M.S., Ph.D.
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 22, 2026, 3:59 AM EDT
Terminated Phase 2 Interventional Results available

Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes

NCT00837759
View directory record Official record
Conditions
Diabetes Mellitus Type 1, Autoimmune Diabetes
Interventions
Insulin, Lansoprazole, Sitagliptin, Diamyd, GAD65 (Diamyd)
Drug · Biological
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
16 Years to 30 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 22, 2026, 3:59 AM EDT
Recruiting Phase 2 Interventional

A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old

NCT07722546
View directory record Official record
Conditions
Graves' Disease
Interventions
Felzartamab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Glendale, Arizona • Los Angeles, California • Doral, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

NCT02924688
View directory record Official record
Conditions
Asthma
Interventions
FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI)
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
2,436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
99
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 22, 2026, 3:59 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of High-Intensity Exercise to Attenuate Cognitive Function Limitations and Train Exercise Habits in Older People Living With HIV

NCT06013579
View directory record Official record
Conditions
HIV Infections, Cognitive Impairment
Interventions
Phase 1 Gym Exercise HIIT, Phase 1 Gym Exercise CME, Phase 2 Home Exercise Coaching Text Messages, Phase 2 Home Exercise Control Text Messages
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 22, 2026, 3:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Yoga, Immune Function, and Health

NCT00371397
View directory record Official record
Conditions
Healthy
Interventions
Hatha Yoga Classes, Movement Control
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 22, 2026, 3:59 AM EDT
Active, not recruiting Not applicable Interventional

Multi-Center Study of Sensory Stimulation to Improve Brain Function

NCT03556280
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia Alzheimers, Dementia, Mild, Dementia, Alzheimer Type, Dementia of Alzheimer Type, Dementia, Cognitive Impairment, Mild, Cognitive Decline
Interventions
GammaSense Stimulation System (Active Settings), GammaSense Stimulation System (Sham Settings)
Device
Lead sponsor
Cognito Therapeutics, Inc.
Industry
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Delray Beach, Florida • Stuart, Florida • Methuen, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 22, 2026, 3:59 AM EDT
Completed No phase listed Observational

User-Friendly Spirometer and Mobile App for Self-Management and Home Monitoring of Asthma Patients

NCT03642418
View directory record Official record
Conditions
Asthma Acute, Asthma in Children, Asthma Chronic, Asthma Attack
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years to 15 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 22, 2026, 3:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Training on Central Auditory Function in Multiple Sclerosis

NCT01023074
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Auditory training, MS: Control Activity
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 22, 2026, 3:59 AM EDT
Completed Not applicable Interventional

Low Dose Cyclosporin and Methotrexate Therapy in Diabetes

NCT00905073
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
cyclosporin and methotrexate
Drug
Lead sponsor
Georgetown University
Other
Eligibility
8 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 1994
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Oct 22, 2026, 3:59 AM EDT
Completed Phase 3 Interventional

A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics

NCT00116883
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X aqueous nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years to 11 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
12
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 22, 2026, 3:59 AM EDT
Active, not recruiting No phase listed Observational

Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology

NCT05757583
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 22, 2026, 3:59 AM EDT
Completed Phase 2 Interventional

Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine

NCT00471614
View directory record Official record
Conditions
HIV Infections, Insulin Resistance, Hyperlactatemia
Interventions
NucleomaxX (contains uridine)
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 22, 2026, 3:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Endothelial Function, Arterial Stiffness and Components

NCT01439217
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
8 Years to 28 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 22, 2026, 3:59 AM EDT
Completed Phase 4 Interventional Results available

Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

NCT00843713
View directory record Official record
Conditions
HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections
Interventions
raltegravir, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 22, 2026, 3:59 AM EDT
Recruiting Not applicable Interventional

WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)

NCT07058064
View directory record Official record
Conditions
Lymphoma, Sarcoma
Interventions
Electrocardiogram, Echocardiogram, LVEF echocardiogram, Apple Watch, Biospecimen collection, Questionnaires, Cardio-pulmonary exercise test, 6 minute walk test, Grip strength test
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 22, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

NCT02396134
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Hodgkin Lymphoma, Adult Non-Hodgkin Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, HLA-A*0201 Positive Cells Present, Myelodysplastic Syndrome, Adult Lymphoblastic Lymphoma, Chronic Lymphocytic Leukemia, Myelofibrosis, Myeloproliferative Neoplasm
Interventions
CMVpp65-A*0201 peptide vaccine, Placebo, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
5
States / cities
Duarte, California • Atlanta, Georgia • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 22, 2026, 3:59 AM EDT
Completed Phase 1 Interventional Results available

Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

NCT01393964
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Dexamethasone, Elotuzumab (BMS-901608; HuLuc63)
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
11
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 22, 2026, 3:59 AM EDT